secwatch.observer — SEC 8-K summary
======================================

Issuer:     Omega Therapeutics, Inc. (—)
CIK:        0001850838
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000950170-24-053194
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omega Therapeutics Q1 net loss $20.1M; cash $60M funds into Q1 2025; OTX-2002 advances
--------------------------------------------------------------------------------

- Net loss of $20.1M for Q1 2024 vs $25.3M in Q1 2023; R&D expenses fell 23% to $15.4M.
- Cash and cash equivalents $60.0M as of March 31, 2024; expected to fund operations into Q1 2025.
- Phase 1/2 MYCHELANGELO I trial of OTX-2002 advanced to Cohort 5 at 0.3 mg/kg; additional data expected mid-2024.
- Presented preclinical data for MYC-targeting epigenomic controller in EGFRi-resistant NSCLC at AACR 2024.
- New preclinical data on durable gene upregulation to be presented at ASGCT 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850838/000095017024053194/0000950170-24-053194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850838/000095017024053194/omga-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer